Ironwood Pharmaceuticals Q3 Adj. EPS $0.12 Misses $0.16 Estimate, Sales $113.74M Beat $112.89M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals reported Q3 adjusted earnings of $0.12 per share, missing the analyst consensus estimate of $0.16 by 25%. This is a 57.14% decrease from the same period last year. However, the company's quarterly sales of $113.74 million beat the analyst consensus estimate of $112.89 million by 0.75%, a 4.70% increase from the same period last year.
November 09, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ironwood Pharmaceuticals' Q3 earnings per share missed estimates by 25%, a 57.14% YoY decrease. However, sales beat estimates by 0.75%, a 4.70% YoY increase.
Ironwood Pharmaceuticals' Q3 earnings per share missed the analyst consensus estimate by 25%, which is a significant decrease from the same period last year. This could negatively impact the company's stock price in the short term. However, the company's sales beat the analyst consensus estimate, which could offset some of the negative impact.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100